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Abstract
Although obstructive sleep apnea (OSA) is known to have a strong familial basis, no genetic polymorphisms influencing
apnea risk have been identified in cross-cohort analyses. We utilized the National Heart, Lung, and Blood Institute (NHLBI)
Candidate Gene Association Resource (CARe) to identify sleep apnea susceptibility loci. Using a panel of 46,449
polymorphisms from roughly 2,100 candidate genes on a customized Illumina iSelect chip, we tested for association with
the apnea hypopnea index (AHI) as well as moderate to severe OSA (AHI$15) in 3,551 participants of the Cleveland Family
Study and two cohorts participating in the Sleep Heart Health Study. Among 647 African-Americans, rs11126184 in the
pleckstrin (PLEK) gene was associated with OSA while rs7030789 in the lysophosphatidic acid receptor 1 (LPAR1) gene was
associated with AHI using a chip-wide significance threshold of p-value,2610
26. Among 2,904 individuals of European
ancestry, rs1409986 in the prostaglandin E2 receptor (PTGER3) gene was significantly associated with OSA. Consistency of
effects between rs7030789 and rs1409986 in LPAR1 and PTGER3 and apnea phenotypes were observed in independent
clinic-based cohorts. Novel genetic loci for apnea phenotypes were identified through the use of customized gene chips
and meta-analyses of cohort data with replication in clinic-based samples. The identified SNPs all lie in genes associated
with inflammation suggesting inflammation may play a role in OSA pathogenesis.
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Obstructive sleep apnea (OSA) is a common disorder charac-
terized by collapse of the upper airway during sleep leading to
recurrent arousals, intermittent hypoxia, and surges in sympathetic
activation. By narrowing the upper airway lumen, obesity is one of
the strongest risk factors for OSA [1]. Independent of obesity,
OSA has been implicated as an independent risk factor in the
development of insulin resistance, hypertension and cardiovascular
disease [2,3,4]. In addition, the fragmentation of sleep caused by
OSA increases the risk of excessive daytime sleepiness and, as a
result, risk of motor vehicle accidents [5,6]. In total, OSA has been
associated with substantial increases in healthcare spending [7].
Numerous studies have established that OSA aggregates within
families suggesting the presence of a genetic predisposition
[8,9,10]. Those with one affected relative are approximately
50% more likely to have OSA themselves [8]. Though obesity
itself has a strong genetic basis, the familial aggregation of OSA
persists even after accounting for obesity [11]. This may be due to
the role of craniofacial morphology, ventilatory drive or other
heritable traits important in OSA pathogenesis. The overall health
impact of OSA and limited treatment options currently available
for this disease underscore the need to better understand its
molecular basis.
While prior genetic studies of OSA have suggested novel
susceptibility loci, these studies have been relatively limited in
terms of sample size. In this work, we sought to combine data from
two of the largest sleep apnea epidemiologic cohorts, the
Cleveland Family Study and the Sleep Heart Health Study, to
identify genetic variants that predict OSA risk in both European
ancestry and African-American populations.
These two cohorts participated in the NHLBI sponsored
Candidate gene Association Resource (CARe) project wherein a
custom candidate gene array assaying 45,237 single nucleotide
polymorphisms (SNPs) over 2000 candidate regions relevant to
heart, lung, blood, and sleep disorders [12], provided the ability to
combine information from multiple cohorts in the search for
genetic variants that influence risk for common diseases.
Results
The CARe consortium included three cohorts with OSA
phenotyping included in this analysis: the Cleveland Family Study
(CFS) and subgroups of the Sleep Heart Health Study recruited
from the Atherosclerosis Risk in Communities (ARIC) study and
the Framingham Heart Study (FHS). In total, 3,551 individuals
from these CARe cohorts were included in the primary analyses –
2,904 individuals of European ancestry (EAs) and 647 African-
Americans (AAs). An additional 1795 individuals from the
Western Australia Sleep Health Study (WASHS) served as a
replication sample for the EA findings and 1010 cases and controls
from the Cleveland Sleep Apnea (CSA) study and Case
Transdisciplinary Research in Energetics and Cancer Colon
Polyps Study (CTRECCPS) respectively served as a replication
sample for AA findings. The sample size and participant
characteristics from each study are shown in Table 1. There
was a fairly even gender distribution in the community-based
cohorts, whereas WASHS had a greater proportion of men as one
would expect in a clinical cohort. In contrast, CSA and
CTRECCPS had greater proportions of women likely reflecting
gender differences in healthcare utilization among African-
Americans [13]. Mean BMI across cohorts ranged from 28 to
41 kg/m
2 suggesting a high prevalence of obesity. The prevalence
of moderate to severe OSA was 29–36% across community-based
cohorts.
Within the primary analytic sample, there was little evidence for
population stratification in the EAs with genomic control inflation
factors (l) of 1.05 and 1.04 for the OSA and logAHI analyses
respectively. Slightly greater l values were obtained for AAs (1.10
for OSA and 1.08 for logAHI). However, after using genomic
control correction, the resulting quantile-quantile plots (Figures
S1,S2,S3,S4) showed no evidence of type I error inflation in any
of the analyses.
African-American Findings
Manhattan plots displaying the strength of association between
logAHI and OSA with each genotyped SNP in AAs are displayed
in Figures 1,2 respectively. One SNP, rs7030789 in an intronic
region of the LPAR1 gene was significantly associated with
logAHI in AAs (Table 2) while a second SNP, rs7972342, in an
intronic region of the ITPR2 gene, just missed the threshold for
statistical significance with a p-value of 2.3610
26. The effects of
these SNPs were reduced slightly in BMI-adjusted models
compared to models not including BMI. However, stratified
analyses revealed the effect of rs7030789 was actually greater in
the non-obese than the obese (b=0.18 vs. 0.09) and the effect of
rs7972342 was similar in both groups (b=20.12 vs. 20.15). Both
SNPs were nominally associated with the dichotomous OSA
phenotype (p=0.007 for rs7030789 and p=0.003 for rs7972342).
One SNP, rs11126184 downstream of the PLEK gene on
chromosome 2 was significantly associated with the dichotomous
OSA phenotype (Table 3). The minor allele in this SNP was
associated with a reduced risk of OSA with an OR of 0.43. The
protective effect of this SNP was not reduced with BMI adjustment
and in fact, stratified analyses suggested a stronger association in
the non-obese (OR=0.26) compared to the obese (OR=0.47)
subgroup. This suggests rs11126184 may influence OSA through
obesity-independent pathways. This SNP was nominally associat-
ed with logAHI (p=0.004).
African-American Replication
Of the three SNPs in AAs with evidence of association,
genotyping of rs7972342 did not meet quality control standards.
The other two SNPs were tested for association with the OSA
phenotype. No evidence of deviation from HWE was found for
either SNP among controls. No evidence for association was found
with rs11126184 (OR=1.03, p=0.40). In contrast, an association
was noted between rs7030789 and OSA status with an OR of 1.29
(p=0.01) for each additional risk allele after adjusting for age, sex,
and BMI.
European Ancestry Findings
Manhattan plots displaying the strength of association between
logAHI and OSA with each genotyped SNP in EAs are displayed
in Figures 3,4 respectively. Among EAs, no SNP met criteria for
a statistically significant association with logAHI. One SNP,
rs1409986, located in an intronic region of the PTGER3 gene
which codes for a prostaglandin E2 receptor was significantly
associated with OSA in EAs (p=1.0610
26), with an OR of 2.1 for
each additional risk allele (Table 3). This SNP did not meet
quality standards in the ARIC cohort. However, between the
other two cohorts, a formal test for heterogeneity (I
2=0.32,
p=0.22) was nonsignificant with an OR=1.82 in CFS and an
OR=2.78 in FHS. The association strengthened with adjustment
for BMI suggesting that this association was not mediated through
obesity. In support of this interpretation, analyses stratified by
obesity status found similar effects for rs1409986 among those with
and without obesity (OR=2.36 vs. 2.37). This SNP was nominally
associated with logAHI (p=0.02).
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The minor allele frequency for rs1409986 in WASHS was 7.3%
with no evidence of deviation from HWE (p=0.38). The OR for
OSA for each risk allele in this cohort adjusting for age, sex, and
BMI was 1.20 (p=0.13). Under an additive model, there was no
association with logAHI (p=0.35). However, under a co-
dominant model, an association was found (p=0.05). While no
difference was found between CT and CC genotypes, the TT
genotype was associated with a 50% greater AHI than the wild
type CC genotype (p=0.02).
Sensitivity Analyses
No change in results for either EAs or AAs was found by
including data from the 354 children in the CFS cohort. In
contrast, results from a third Sleep Heart Health Study cohort, the
Cardiovascular Health Study (CHS), did not support findings for
either ethnic group. Note that this cohort was on average more
than 10 years older than both ARIC and FHS with an even
greater age difference with CFS.
Comparing results across ethnic groups, the prevalence of the
minor allele for rs1409986 (PTGER3) in AAs was only 2%,
precluding accurate estimation of its effect in this population.
Among the top three SNPs for apnea-related traits identified in
AAs, rs7030789 (LPAR1) showed evidence for association to an
apnea phenotype in EAs with p=0.01 for association to OSA and
p=0.06 to logAHI.
Discussion
This study represents one of the first systematic evaluations of a
large number of genetic loci identified as relevant to heart, lung,
blood, and sleep phenotypes in relationship to sleep apnea. OSA
represents one of the most common sleep disorders with a
prevalence of 2 to 4% in children and greater than 10% in adults
[14,15]. The substantial neurocognitive and cardiovascular
morbidity attributed to OSA as well as the likely rising prevalence
Table 1. Characteristics of the Study Participants.
European Ancestry African-Americans
Cohorts ARIC (n=1673) FHS (n=567) CFS (n=664)
WASHS
(n=1795) CFS (n=647) CSA (n=459) CTRECCPS (n=551)
Age (yrs) 62.565.7 59.269.0 41.3619.6 51.5613.2 38.6619.2 49.1614.4 56.068.8
Male 47% 48% 47% 63% 43% 33% 31%
BMI (kg/m
2) 28.965.1 28.365.1 30.168.7 32.967.8 31.969.9 40.669.9 31.167.0
AHI (events/hr) 9.1 (3.7, 19.0) 8.0 (3.1, 17.7) 4.7 (1.4, 18.3) 28.5 (16.0, 50.7) 5.9 (1.5, 21.8) 39.2 (5.0, 192.5) —
OSA 33% 29% 36% 77% 36% 100% 0%
Values displayed are means 6 standard deviation or median (interquartile range) for continuous variables and percentages for dichotomous variables. OSA is defined as
an AHI$15 for ARIC, FHS, CFS, and WASHS, based on an AHI$5 plus clinical symptoms for CSA, and based on physician diagnosis for CTRECCPS.
AHI: apnea hypopnea index; BMI: body mass index; OSA: obstructive sleep apnea.
doi:10.1371/journal.pone.0048836.t001
Figure 1. Manhattan plot for apnea hypopnea index in African-Americans. This figure plots the association results for all SNPs against
log(apnea hypopnea index +1) among African-Americans. The y-axis displays the -log(p-value), the x-axis the SNP position on each chromosome. The
dotted line represents the threshold for statistical significance based on the number of independent comparisons being made.
doi:10.1371/journal.pone.0048836.g001
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understanding the genetic basis for this disease an important
priority. Using genetic studies to identify novel molecular
pathways involved in OSA pathogenesis may allow for the
development of new treatments for this disorder – an important
goal given the relatively poor tolerance of current treatment
options.
Using data collected from three large cohorts and a genotyping
platform that selected for candidate genes relevant to cardiovas-
cular, respiratory and sleep physiology, we identified several SNPs
associated with OSA related phenotypes.
Among AAs, the lysophosphatidic acid receptor 1 (LPAR1) gene
was identified as a potential susceptibility locus. The rs7030789
SNP in an intronic region of LPAR1 was significantly associated
with AHI in the discovery sample, demonstrated nominal
association with the OSA phenotype in the CARe dataset as well
as in the replication analysis comparing clinical OSA cases to
controls. In addition, this locus showed evidence for replication in
EAs strengthening the evidence base for a true susceptibility locus
near this SNP. A locus close to LPAR1 has been shown to increase
LPAR1 expression and subsequently increase circulating mono-
cyte numbers [16,17], suggesting a pro-inflammatory role for this
gene. In addition, LPAR1 is expressed in proliferating regions of
the embryonic cerebral cortex [18]. An LPAR1 knockout mouse
model has been found to have abnormal innate behaviors as well
as craniofacial abnormalities [19], suggesting potential neural
and/or skeletal mechanisms for OSA pathogenesis.
The other loci identified in the CARe cohorts included one in
plekstrin (PLEK), which is a substrate for protein kinase C in
platelets and a wide range of leukocytes including monocytes and
macrophages. This gene plays a role in actin assembly; knock out
of PLEK in mouse models results in defective exocytosis [20]. In
addition, there was suggestive evidence for an association with a
locus in the gene for the inositol triphosphate receptor 2 (ITPR2).
The ITPR2 gene plays a central role in intra-cellular calcium
regulation, which is vital to cellular stability, cellular adhesion, and
second messenger activity. Prior candidate gene studies have
associated SNPs in ITPR2 with markers of inflammation and
endothelial dysfunction as well as blood pressure phenotypes
[21,22]. Together with the LPAR1 findings, these results suggest
alterations in inflammatory pathways including monocyte/mac-
rophage function may be particularly important in OSA
pathogenesis among AAs as well as the possibility of overlapping
pathways that may mediate both hypertension and OSA.
However, this connection between loci associated with inflamma-
tion and OSA cannot distinguish between the possibilities that
inflammation is a primary causal factor for OSA versus that
inflammation plays a secondary role in increasing OSA severity
among those with an underlying predisposition.
In EAs, a polymorphism in PTGER3, a prostaglandin E2
receptor, was significantly associated with OSA. In a replication
analysis using data from a clinic-based cohort which had a skewed
distribution of AHI due to high representation of patients with
sleep apnea or sleep apnea symptoms, this SNP was associated
with an incremental increase in disease severity as measured by the
AHI level. Although association with the dichotomous trait OSA
was not replicated, this may be due to limited power for this trait
since nearly 80% of subjects in the WASHS cohort met OSA
criteria. The PTGER3 gene is expressed in neuronal tissue and
modulates neurotransmitter release in both central and peripheral
neurons. A haplotype analysis of PTGER3 recently suggested this
gene may represent a risk factor for hypertension [23]. Unfortu-
nately, sleep apnea was not characterized in that study.
It is important to note that our findings were not replicated in
the Cardiovascular Health Study. This cohort is substantially older
than the cohorts from which the primary results are based and the
mechanisms underlying OSA in the elderly may differ substan-
tially from OSA in middle aged populations. For example, obesity
plays a much weaker role in the elderly while issues related to
ventilatory control are much more prominent as evidenced by the
greater number of central events in older individuals. Only one of
the associations (rs7030789 in LPAR1) could be replicated across
Figure 2. Manhattan plot for obstructive sleep apnea in African-Americans. This figure plots the association results for all SNPs against an
apnea hypopnea index of 15 or greater among African-Americans. The y-axis displays the -log(p-value), the x-axis the SNP position on each
chromosome. The dotted line represents the threshold for statistical significance based on the number of independent comparisons being made.
doi:10.1371/journal.pone.0048836.g002
Association of Genetic Loci with Sleep Apnea
PLOS ONE | www.plosone.org 4 November 2012 | Volume 7 | Issue 11 | e48836both EAs and AAs. This may be due to differences in allele
frequencies impacting power (as for rs1409986 in PTGER3),
differences in linkage disequilibrium structure or other ancestry
related effects.
A prior analysis of CFS data has also utilized a candidate gene
approach [24]. In that study, 53 candidate genes for OSA were
genotyped and three loci were identified meeting chip-wide
significance criteria, 2 in EAs (loci in C-reactive protein - CRP
and glial cell derived neurotrophic factor - GDNF) and 1 in AAs
(locus in serotonin 2A receptor - HTR2A). None of the top loci
from this study were included as candidate genes in the prior
report and one of the top loci from that report (GDNF) was not
genotyped on the IBC platform used here. For the two
overlapping loci (CRP and HTR2A), associations with apnea
phenotypes were again confirmed among CFS EAs and AAs,
although the level of statistical significance did not meet the stricter
threshold used in this paper due to the greater number of SNPs
interrogated. Of note, the CRP locus did not replicate among EAs
from ARIC and FHS, demonstrating the importance of replication
cohorts.
Of interest, although the African American sample was
relatively small, it was derived from a single cohort that was
assembled explicitly to enhance the power to detect genetic
associations through recruitment of affected probands and
multiplex families. OSA is common in minority populations and
prior segregation analyses found stronger transmission of one or
several alleles in AAs compared to EA families [25]. Although
genetic studies in AAs may be limited by the coverage patterns of
existing chips, the genetic diversity of this admixed population also
provides opportunities to identify novel variants and to perform in
silico ‘‘fine mapping’’ [26]. Despite the sample size, we identified
two loci significantly associated with sleep apnea phenotypes in
AAs and a third nearly significant association. Furthermore, we
were able to replicate the strongest finding in an independent
sample.
Strengths of this study include its use of standardization in both
phenotyping and genotyping across several cohorts. For the
primary analyses, sleep apnea was objectively measured from
overnight polysomnography by a central laboratory minimizing
measurement error and all genotyping was conducted by a single
laboratory. The use of a broadly defined candidate gene approach
(i.e., with genes selected for heart, lung, blood and sleep traits)
provides balance in examining relevant but not narrowly defined
susceptibility loci without the statistical penalties incurred by using
a genome-wide association approach. This is particularly relevant
for conditions such as OSA that are expensive to phenotype. On
the other hand, this approach is not amenable to identifying
completely novel loci.
We also conducted analyses in parallel to identify loci important
in both African-Americans and those of European ancestry.
Demonstrating a similar pattern of association between apnea
phenotypes and rs7030789 in both groups provides additional
evidence as to the presence of a true association. Another strength
of the current study is the use of both principal component
adjustment and genomic control correction to prevent inflation of
the false positive rate due to cryptic population stratification or
other sources of bias. Nevertheless, additional analyses from
independent cohorts are needed to replicate the findings presented
in this study.
Limitations of the work include the relatively small number of
cohorts included and modest sample size compared to other cross-
cohort genetic analyses. Unfortunately, few cohorts with detailed
sleep apnea phenotyping as well as genotyping currently exist,
particularly in minority populations. This limited our opportunity
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confirm our findings. Furthermore, it should be noted that no
functional data are yet available to demonstrate a direct effect of
any of the variants identified with pathophysiological changes
relevant to OSA.
Overall, the relatively small number of loci identified and
replicated in this study presumably reflects a combination of the
limited power to detect variants with low prevalence or small effect
sizes and that many of the genetic variants contributing to OSA
risk are either rare, have fairly modest effects, or both. This is in
line with current views that OSA represents a complex disease
having many genetic and environmental contributors each of
which explains a relatively small proportion of the total
attributable risk. The limited success in identifying genetic
determinants of OSA might also reflect heterogeneity in genetic
etiology across the various cohorts studied which differ in mean
age and BMI. In fact, the association between OSA and
rs7030789 appeared to be much stronger among leaner individ-
uals. Another possible explanation is that causal variants with
relatively large effects may exist in regions of the genome that were
not interrogated in this candidate gene approach. Genome wide
association (GWA) study designs will be required to assess whether
such variants exist.
In summary, our results identify several loci, each of which has
been implicated in inflammation, associated with a sleep apnea
phenotype. While much work has focused on the potential pro-
inflammatory effect of OSA, inflammation may play a causal role
in OSA pathogenesis as well. Inflammation is prominent in both
the mucosal and muscular layers of upper airway tissues of patients
with OSA [27,28]. In addition, inflammation may also impact
ventilatory or sleep-wake control mechanisms relevant to OSA
pathogenesis.
Of note, though all of the cohorts studied had a high prevalence
of obesity, the identified associations were independent of obesity
supporting the importance of identifying pathways leading to OSA
within an obese population. Additional studies are needed to
better understand the molecular pathways that increase suscepti-
bility to this highly prevalent disorder, the overlap of such
pathways with ones that also mediate cardiopulmonary disorders,
Table 3. SNPs associated with OSA.
BMI-Adjusted BMI-Unadjusted
Ethnicity SNP Gene Chr Position
Minor
Allele
Major
Allele
Minor Allele
Frequency I
2 P-value*
OR (95%
CI) P-value
OR
(95%
CI) P-value
African-
American
rs11126184 PLEK 2 68505678 A C 0.378 — 0.36 0.43 (0.31,
0.60)
1.54610
26 0.45
(0.33,
0.62)
1.41610
26
European
Ancestry
rs1409986 PTGER3 1 71104086 A G 0.075 32% 0.23 2.14 (1.58,
2.90)
1.01610
26 1.77
(1.30,
2.41)
2.21610
24
*Heterozygosity P-value for European ancestry cohorts and Hardy-Weinberg P-value for African-Americans.
doi:10.1371/journal.pone.0048836.t003
Figure 3. Manhattan plot for apnea hypopnea index in the European ancestry population. This figure plots the association results for all
SNPs against log(apnea hypopnea index +1) among those of European ancestry. The y-axis displays the -log(p-value), the x-axis the SNP position on
each chromosome. The dotted line represents the threshold for statistical significance based on the number of independent comparisons being
made.
doi:10.1371/journal.pone.0048836.g003
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Materials and Methods
Study Sample
The CARe Consortium is a NHLBI supported resource for
analyses of the association of genotypes with heart, lung, blood,
and sleep phenotypes. CARe is composed of 9 large cohort studies
of which four have collected polysomnographic data in at least a
subset. These are the Cleveland Family Study (CFS), and subsets
of three cohorts – the Atherosclerosis Risk in Communities (ARIC)
study, the Cardiovascular Health Study (CHS), and the Framing-
ham Heart Study (FHS) – which participated in the Sleep Heart
Health Study (SHHS). Because the OSA phenotype changes
across the lifespan with differing risk factors in pediatric, middle-
aged, and elderly populations, we focused on the middle-aged.
Thus, all children (age,18 yrs) from the CFS cohort and the
entire CHS cohort (with mean age at the time of OSA
phenotyping of 72 yrs) were excluded from the primary analyses.
CFS is a family-based longitudinal cohort study designed to
study the genetic basis of OSA [8]. Index probands with a
laboratory confirmed diagnosis of OSA, and at least two first-
degree relatives available to be studied were recruited along with
family members. Initially, neighborhood controls and their
relatives were also recruited. Overall, a total of 2284 individuals
from 361 families were recruited from the Cleveland metropolitan
area. DNA was available in a subset of 1665 individuals for CARe
genotyping. Phenotype data was used from the last available exam.
SHHS is a prospective cohort of 6,441 subjects who underwent
polysomnography recruited from six established cohorts to study
the effects of OSA on cardiovascular disease [29]. Three of the six
parent cohorts contributing to SHHS, ARIC, FHS, and CHS,
participated in CARe and so contributed genetic material. SHHS
recruited subjects over the age of 40 with oversampling of those
reporting a history of snoring at some sites. Full details have been
previously published [29].
ARIC is a longitudinal cohort study of atherosclerosis and its
clinical sequelae. From 1987 to 1989, a population-based sample
of 15,792 men and women aged 45 to 64 years were recruited
from 4 US communities (Forsyth County NC, Jackson MS,
suburban Minneapolis MN, and Washington County MD). SHHS
recruited 1000 ARIC participants in Minneapolis and 750
participants from Washington County, with oversampling of
habitual snorers.
The FHS started in 1948 with 5209 randomly ascertained adult
participants from Framingham, MA. In 1971, the Offspring
cohort (comprised of 5124 individuals who were children of the
original cohort participants or the children’s spouses) was created.
SHHS recruited 699 FHS participants from the Offspring cohort,
all of European ancestry.
The Western Australia Sleep Health Study (WASHS) is a
prospective cohort study of patients referred to the sole public
sleep clinic in Western Australia. It has been designed to identify
the genetic basis of sleep disorders and co-morbidities [30]. The
vast majority (91%) of participants were referred for sleep apnea.
Recruitment began in 2006. The cohort is predominantly of
European ancestry. Analyses are limited to the first 1795
individuals of European ancestry with both DNA and sleep
phenotyping available.
The Case Sleep Apnea (CSA) cohort recruited patients referred
for evaluation of obstructive sleep apnea in the University
Hospitals Case Medical Center sleep disorders clinic and
laboratory from 2007 to 2010. Of 945 patients diagnosed with
OSA based on symptoms and an AHI.5, 475 reported African-
American background. Of these genotyping was successfully
performed on 459.
These cases were matched against controls derived from the
Case Transdisciplinary Research in Energetics and Cancer Colon
Polyps Study (CTRECCPS) cohort. Description of this cohort has
Figure 4. Manhattan plot for obstructive sleep apnea in the European ancestry population. This figure plots the association results for all
SNPs against an apnea hypopnea index of 15 or greater among those of European ancestry. The y-axis displays the -log(p-value), the x-axis the SNP
position on each chromosome. The dotted line represents the threshold for statistical significance based on the number of independent comparisons
being made.
doi:10.1371/journal.pone.0048836.g004
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routine screening colonoscopy at an endoscopy center affiliated
with University Hospitals Case Medical Center were recruited
providing a study base similar to that for the CSA cohort. Of 1259
subjects recruited from 2006 to 2009, 600 reported African-
American background. Forty-nine individuals reporting a clinical
diagnosis of sleep apnea were excluded from this analysis leaving a
control sample size of 551.
The protocols for creating each of the cohorts and data
collection were approved by the Institutional Review Board or
Ethics Committee at Partners Health Systems (CARe), Johns
Hopkins University (ARIC), University of Minnesota (ARIC),
University Hospitals Case Medical Center (CFS, CSA,
CTRECCPS), Boston University Medical Center (FHS), and Sir
Charles Gairdner Hospital (WASHS) and all participants provided
written informed consent.
Sleep Apnea Phenotyping
Quantification of sleep apnea severity was done using poly-
somnography as part of either the SHHS or the CFS, using
techniques that have been previously described [32,33]. In brief,
SHHS participants underwent in-home polysomnography using
the Compumedics P Series System (Abbotsville, Australia) while
CFS participants underwent in laboratory polysomnography using
the Compumedics E series system or in-home sleep studies with
measurement of oximetry, effort, thermistry, and body position
(Edentec, Eden Prairie, MN). Indices derived from either
technique were highly correlated [34]. Scoring of both sleep and
breathing was done in a standardized fashion across SHHS and
CFS by the same Reading Center at Case Western Reserve
University [32]. Apneas were defined as no airflow for 10 seconds
while hypopneas were defined as a 30% reduction in airflow
accompanied by a 3% desaturation or arousal. Overnight in-
laboratory polysomnography was performed in WASHS and the
Case Sleep Apnea cohort and the AHI was computed using similar
scoring criteria as recommended by the American Academy of
Sleep Medicine [35]. Two phenotypes were assessed for associ-
ation with candidate SNPs. A quantitative trait, apnea hypopnea
index, was log-transformed (after adding 1) to approximate a
normal distribution. In addition, the dichotomous trait OSA,
defined as an AHI$15, was assessed.
Covariate Assessment
Age, gender, and ethnic background were obtained by self-
report. Height and weight were measured in a standardized
fashion in each cohort and body mass index (BMI) calculated as
the ratio of weight to height squared.
Genotyping
Genotyping was performed at the Broad Institute utilizing an
IBC 50K SNP array which was custom designed as a gene-centric
single nucleotide polymorphism (SNP) genotyping array that
contains greater SNP marker density and linkage disequilibrium
coverage for over 2000 candidate regions relevant to heart, lung,
blood and sleep disorders than current genome-wide arrays,
including approximately 7800 SNPs not present in the HapMap.
Candidate loci were identified based on a literature search as well
as pathway-based tools for relevant biologic pathways, and
unpublished cardiovascular expression quantitative trait loci
(eQTL) and GWA data. Loci were selected for coverage based
on a voting process by consortium investigators to rank loci by
importance. Further details have been previously published [12].
A total of 45,237 candidate SNPs were genotyped on the IBC
array. The tagging approach utilized on the IBC array was
designed to capture maximal genetic information from the
HapMap populations as well as European and African American
individuals from the SeattleSNPs and NIEHS sequencing
programs [12]. Only SNPs with a MAF of 5% or greater were
included in these analyses due to concerns for unstable point
estimates and inflated type 1 error. SNPs were clustered into
genotypes using the Illumina Beadstudio software and subjected to
quality control filters at the sample and SNP level, separately
within each cohort. Samples were excluded for individual call rates
,90%, gender mismatch and duplicate discordance. SNPs were
removed for call rates ,95% or Hardy-Weinberg equilibrium
(HWE) p,10
25 in analyses of individuals of European ancestry
(EAs). Because of expected admixture, no HWE filtering was used
for African-Americans (AAs).
Statistical Analysis
Principal Components Analysis (PCA). Principal compo-
nents were generated using EIGENSTRAT within each cohort
using the CARe genotype data in order to control for population
stratification [36,37]. Two reference populations were included in
the principal component analysis of AAs: 1,178 European
Americans from a multiple sclerosis GWA study (from Dr. Phil
de Jager and colleagues), and 756 Nigerians from the Yoruba
region from a hypertension GWA (provided by Dr. Richard
Cooper and colleagues). Importantly, these two samples under-
went extensive quality control procedures to remove population
outliers using PCA. Ten principal components were generated for
each cohort.
Within Cohort Analysis. All data analyses were performed
separately for EAs and AAs. To further adjust for population
stratification, the first 10 principal components were incorporated
as covariates in all analyses. Primary analyses adjusted for BMI to
identify variants whose actions were independent of obesity.
Secondary analyses assessed the strength of association without
BMI adjustment.
Analyses were carried out using a linear or logistic statistical
framework for logAHI and OSA respectively in PLINK V 1.0.7
[38], or, for cohorts that included related individuals (CFS and
FHS), R scripts that model family structure were used [39].
Consistency of findings was evaluated by comparing results in
secondary analyses stratified on obesity status as defined by a
BMI$30 kg/m
2.
Meta-analysis. For EAs, results from each of the three
cohorts (CFS, ARIC, FHS) were combined using a fixed effects
meta-analysis with an inverse-variance weighted approach as
implemented in METAL [40]. Heterogeneity was assessed using
the I
2 inconsistency metric. No meta-analysis was required for AAs
as only CFS had sufficient AAs for analysis.
Genomic Control. Genomic control correction was applied
after calculating the genomic control inflation factor (l) using
METAL based on the results of the meta-analysis performed in
EAs or in the CFS cohort alone for AAs.
Significance Criterion. To correct for multiple testing, we
determined the effective number of independent tests as 26,482 for
AA and 20,544 for EA based on the correlation structure among
the SNPs estimated using the spectral method [41,42]. To
maintain an overall type 1 error rate of 5%, a statistical threshold
of a=2 610
26 was used to declare array-wide significance.
Replication Analyses. Replication of EA findings was
assessed using the WASHS cohort while replication of AA findings
used case control data with cases from the CSA cohort and
controls from the CTRECCPS cohort. Statistical analyses were
done using linear and logistic regression for logAHI and OSA
Association of Genetic Loci with Sleep Apnea
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values were computed.
Supporting Information
Figure S1 Quantile-quantile plot for apnea hypopnea index in
African-Americans. This figure plots expected versus observed p-
values from the association analyses of all SNPs against log(apnea
hypopnea index+1) in African-Americans. The plotted observed p-
values are after accounting for genomic control.
(TIF)
Figure S2 Quantile-quantile plot for obstructive sleep apnea in
African-Americans. This figure plots expected versus observed p-
values from the association analyses of all SNPs against an apnea
hypopnea index of 15 or greater in African-Americans. The
plotted observed p-values are after accounting for genomic
control.
(TIF)
Figure S3 Quantile-quantile plot for apnea hypopnea index in
European ancestry individuals. This figure plots expected versus
observed p-values from the association analyses of all SNPs against
log(apnea hypopnea index+1) in those of European ancestry. The
plotted observed p-values are those from the meta-analysis after
accounting for genomic control.
(TIF)
Figure S4 Quantile-quantile plot for obstructive sleep apnea in
European ancestry individuals. This figure plots expected versus
observed p-values from the association analyses of all SNPs against
an apnea hypopnea index of 15 or greater in those of European
ancestry. The plotted observed p-values are those from the meta-
analysis after accounting for genomic control.
(TIF)
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